Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Recent preclinical and retrospective clinical data have suggested that dexamethasone might
sensitize leukemic cells to chemotherapy-induced cell death and thus limit the risk of
leukemic regrowth and relapse. Moreover, it has been experimentally shown that leukemic cells
in acute myeloid leukemia patients who relapse become sensitive to glucocorticoids treatment
highlighting a novel potential role for dexamethasone in relapsed or refractory acute myeloid
leukemia (R/R).
This study was designed to determine whether adding dexamethasone to standard salvage therapy
in the treatment of relapsed/refractory acute myeloid leukemia in adult patients (intensive
chemotherapy amsacrine-cytarabine or azacitidine according to investigator's willingness)
results in a significant improvement of the overall survival.